Resultados de la búsqueda 31-40 of 14617 for Tyrosine

  1. Hematología - Ensayos clínicos - Mayo Clinic

    This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

  3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...

  4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...